Johnson & Johnson MedTech’s MONARCHâ„¢ Platform demonstrated 98.7% navigation success and 83.2% diagnostic yield in the TARGET study, confirming its safety and efficacy for robotically assisted bronchoscopy.
Explore the frontiers of Biotechnology, Pharma/Biopharma industry and Science with BiotechReality. We publish news, reports, views and articles.
Johnson & Johnson MedTech’s MONARCHâ„¢ Platform demonstrated 98.7% navigation success and 83.2% diagnostic yield in the TARGET study, confirming its safety and efficacy for robotically assisted bronchoscopy.
A SciRealityPress Associate
Contents in the website is licensed under CC BY-NC 4.0
Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio